Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:47:48.009Z.
Calculation as of: 2026-10-06T19:47:48.009Z.
Quote observation: 2026-10-06T19:45:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 12822cf5764c24a0ef00c724f2a960962c8ab94682162e48d6be38065653aaef
PE RATIO
N/A
Market Cap
$10.26B
PE Ratio
1034.34
TTM Avg
232.01
3Y Avg
88.58
5Y Avg
62.84
Market Cap
$9.85B
PE Ratio
238.99
TTM Avg
2667.34
3Y Avg
1448.16
5Y Avg
807.09
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | $10.15B | N/A | N/A | N/A | N/A |
| Align Technology, Inc. (ALGN)vs › | $10.12B | 24.52 | 29.33 | 36.97 | 43.63 |
| 10x Genomics, Inc. (TXG)vs › | $10.21B | N/A | N/A | N/A | N/A |
| Molina Healthcare, Inc. (MOH)vs › | $10.26B | 1034.34 | 232.01 | 88.58 | 62.84 |
| The Ensign Group, Inc. (ENSG)vs › | $10.00B | 26.89 | 30.75 | 30.60 | 27.70 |
| Globus Medical, Inc. (GMED)vs › | $10.26B | 19.56 | 23.16 | 68.06 | 56.60 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.92B | 44.66 | 33.97 | 32.01 | 20.98 |
| Repligen Corporation (RGEN)vs › | $9.85B | 238.99 | 2667.34 | 1448.16 | 807.09 |
| Twist Bioscience Corporation (TWST)vs › | $10.49B | N/A | N/A | N/A | N/A |
| Krystal Biotech, Inc. (KRYS)vs › | $9.63B | 40.94 | 40.13 | 207.84 | 207.84 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$9.70
Forward EPS (Est.)
$-0.96
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
